In the original article, there are some incorrect data in the BResults^section of the Abstract. The corrected BResultsŝ ection is as follows:
Results: In total, 10 (14%) patients in the WLS Forte® group versus 23 (30%) patients in the sMVS group developed a deficiency. The costs for the WLS Forte® supplement were €30 versus €21 for sMVS. Additional return visits and associated costs for medical staff were the largest costs, up to 34% in the sMVS group. Total costs for supplementation with sMVS were €306 versus €216 for WLS Forte®.
